FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC trial. Imfinzi shows median overall survival of 55.9 months versus ...

AstraZeneca received a notification from a Chinese customs office regarding unpaid import duties totaling $0.9 million, which the company believes is related to Imfinzi and Imjudo.

FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder cancer, with decision expected in Q2 2025. Imfinzi regimen showed a 32% reduced risk of disease progression ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi (durvalumab) to treat adult patients with limited ...

Imfinzi is already a massive moneymaker for AstraZeneca. It's an immuno-oncology drug that helps the immune system find tumor cells camouflaging themselves behind a common protein called PD-L1.

Written by Zacks Equity Research for Zacks -> AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States.

AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with IMJUDO as well as other novel immunotherapies and modalities.

AstraZeneca strives to redefine cancer care and help transform outcomes for patients with IMFINZI as a monotherapy and in combination with IMJUDO as well as other novel immunotherapies and modalities.

WILMINGTON, Del. -- (BUSINESS WIRE)-- AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) has been accepted and granted Priority Review in the US for the ...